T Cell Specific Surface Glycoprotein CD28 Market Report 2026

The t cell specific surface glycoprotein cd28 market size has grown strongly in recent years. It will grow from $1.62 billion in 2025 to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to early identification of cd28 as a t-cell co-stimulatory receptor, growing immunology research, increasing prevalence of autoimmune diseases, rising cancer research initiatives, limited availability of monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to development of lulizumab pegol and novel cd28 inhibitors, expansion of preclinical and clinical trials, integration of cd28-targeted therapies in autoimmune and cancer treatments, rising investment in biopharmaceutical research, advancement in immunomodulation and monoclonal antibody engineering. Major trends in the forecast period include increasing adoption of flow cytometry and elisa technologies, growth in immunology and cancer research applications, rising development of novel cd28 inhibitors and biobetters, expansion of stem cell and autoimmune disease research, integration of lulizumab pegol in preclinical and clinical studies.

The heightened focus on personalized medicine is poised to accelerate the T cell-specific surface glycoprotein CD28 market ahead. Personalized medicine tailors therapies to patients' unique genetics, surroundings, and habits for superior results and care. Its surge arises from genomic tech progress, pinpointing variations for bespoke interventions. T cell-specific surface glycoprotein CD28 bolsters personalized medicine via precise immune tuning, sharpening therapy impact. It lifts outcomes by fine-tuning T cell responses to patient needs. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US nonprofit, reported FDA approvals for 26 new personalized medicines in 2023, up from 12 in 2022. Thus, the intensifying personalized medicine push is propelling the T cell-specific surface glycoprotein CD28 market.

Key players in the T cell-specific surface glycoprotein CD28 market are advancing novel offerings like combination immunotherapies to amplify T cell engagement, tumor combat, and patient gains. Combination immunotherapies merge immune tactics to supercharge disease-fighting capacity. For instance, in February 2025, Rondo Therapeutics Inc., a US biopharma, shared preclinical results on RNDO 564, a pioneering CD28 Nectin-4 bispecific antibody for late-stage bladder cancer. It sparks CD28 selectively on T cells when grabbing Nectin-4 on tumors, boosting kill power with low spillover harm. Preclinical models showed strong anti-tumor punch, paving for metastatic urothelial carcinoma use.

In December 2024, Rondo Therapeutics Inc., a US biopharma leader, teamed with Eli Lilly and Company to craft fresh CD28 bispecifics for solid tumors. This alliance heightens T cell boosts and anti-tumor immunity while curbing toxicity, ushering advanced immuno-oncology options. Eli Lilly and Company is a US biopharma trailblazer in CD28-focused immuno-oncology therapies.

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the t cell specific surface glycoprotein cd28 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the T Cell Specific Surface Glycoprotein CD28 market by increasing costs of imported monoclonal antibodies, laboratory reagents, and advanced diagnostic instruments such as flow cytometers and ELISA kits. Research laboratories, hospitals, and pharmaceutical companies in regions like North America and Europe, which rely heavily on imports, are most affected. While tariffs have led to higher operational costs and slowed supply chains, they have also encouraged domestic production, investment in local R&D, and development of cost-effective CD28-targeted therapies.

The t cell specific surface glycoprotein cd28 market research report is one of a series of new reports that provides t cell specific surface glycoprotein cd28 market statistics, including t cell specific surface glycoprotein cd28 industry global market size, regional shares, competitors with a t cell specific surface glycoprotein cd28 market share, detailed t cell specific surface glycoprotein cd28 market segments, market trends and opportunities, and any further data you may need to thrive in the t cell specific surface glycoprotein cd28 industry. This t cell specific surface glycoprotein cd28 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

T cell-specific surface glycoprotein CD28 is a co-stimulatory receptor found on most T cells. It binds to B7 molecules (CD80/CD86) on antigen-presenting cells, providing crucial secondary signals that support T cell activation, proliferation, and survival. Its primary role is to enhance immune responses by promoting cytokine production and preventing T cell anergy.

The main types of T cell-specific surface glycoprotein CD28 include FPT155, FR104, Lulizumab Pegol, and others. FPT155 is an investigational therapeutic protein that acts as an immune co-stimulatory fusion protein, targeting CD80 to activate T cells and boost anti-tumor immune responses. These products employ technologies such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), western blotting, and immunohistochemistry, and are distributed through direct sales, distributors, e-commerce, retail pharmacies, and wholesalers. They are applied in immunology research, cancer research, autoimmune diseases, infectious diseases, and stem cell research, serving end users including hospitals, research laboratories, academic institutions, pharmaceutical companies, and diagnostic laboratories.

The T cell-specific surface glycoprotein CD28 market consists of revenues earned by entities by providing services such as drug discovery, antibody development, cell signaling assays, immuno-oncology research, diagnostic testing, and clinical trial support targeting CD28 pathways. The market value includes the value of related goods sold by the service provider or included within the service offering. The T cell-specific surface glycoprotein CD28 market also includes sales of CD28 fusion proteins, CD28 ligands, flow cytometry reagents, and diagnostic assays and kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.